Page 1096 - Hematology_ Basic Principles and Practice ( PDFDrive )

969.e10 Part VII Hematologic Malignancies

408. Jadersten M, Montgomery S, Dybedal I, et al: Long-term outcome of 430. Neukirchen J, Fox F, Kündgen A, et al: Improved survival in MDS
treatment of anemia in MDS with erythropoietin and G-CSF. Blood patients receiving iron chelation therapy - a matched pair analysis of 188
106(3):803–811, 2005. patients from the Düsseldorf MDS registry. Leuk Res 36(8):1067–1070,
409. Engelfriet CP, Reesink HW, Klein HG, et al: International forum: 2012.
granulocyte transfusions. Vox Sang 79(1):59–66, 2000. 431. Malcovati L, Porta MGD, Pascutto C, et al: Prognostic factors and
410. Freifeld AG, Bow EJ, Sepkowitz KA, et al: Clinical practice guideline life expectancy in myelodysplastic syndromes classified according
for the use of antimicrobial agents in neutropenic patients with cancer: to WHO criteria: a basis for clinical decision making. J Clin Oncol
2010 Update by the Infectious Diseases Society of America. Clin Infect 23(30):7594–7603, 2005.
Dis 52(4):427–431, 2011. 432. Takatoku M, Uchiyama T, Okamoto S, et al: Retrospective nationwide
411. Cornely OA, Maertens J, Winston DJ, et al: Posaconazole vs. flucon- survey of Japanese patients with transfusion-dependent MDS and
azole or itraconazole prophylaxis in patients with neutropenia. N Engl aplastic anemia highlights the negative impact of iron overload on
J Med 356(4):348–359, 2007. morbidity/mortality. Eur J Haematol 78(6):487–494, 2007.
412. Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, et al: Acyclovir 433. Jensen PD, Heickendorff L, Pedersen B, et al: The effect of iron chela-
prophylaxis and fever during remission-induction therapy of patients tion on haemopoiesis in MDS patients with transfusional iron overload.
with acute myeloid leukemia: a randomized, double-blind, placebo- Br J Haematol 94(2):288–299, 1996.
controlled trial. J Clin Oncol 15(6):2269–2274, 1997. 434. Guariglia R, Martorelli MC, Villani O, et al: Positive effects on hemato-
413. Kantarjian H, Giles F, List A, et al: The incidence and impact of throm- poiesis in patients with myelodysplastic syndrome receiving deferasirox
bocytopenia in myelodysplastic syndromes. Cancer 109(9):1705–1714, as oral iron chelation therapy: a brief review. Leuk Res 35(5):566–570,
2007. 2011.
414. Neukirchen J, Blum S, Kuendgen A, et al: Platelet counts and haem- 435. Leitch HA, Chan C, Leger CS, et al: Improved survival with iron chela-
orrhagic diathesis in patients with myelodysplastic syndromes. Eur J tion therapy for red blood cell transfusion dependent lower IPSS risk
Haematol 83(5):477–482, 2009. MDS may be more significant in patients with a non-RARS diagnosis.
415. Gonzalez-Porras JR, Cordoba I, Such E, et al: Prognostic impact of Leuk Res 36(11):1380–1386, 2012.
severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer 436. Rose C, Brechignac S, Vassilief D, et al: Does iron chelation therapy
117(24):5529–5537, 2011. improve survival in regularly transfused lower risk MDS patients? A
416. Rebulla P, Finazzi G, Marangoni F, et al: The threshold for prophylactic multicenter study by the GFM (Groupe Francophone des Myélodys-
platelet transfusions in adults with acute myeloid leukemia. Gruppo plasies). Leuk Res 34(7):864–870, 2010.
Italiano Malattie Ematologiche Maligne dell’Adulto. N Engl J Med 437. Mainous AG, Tanner RJ, Hulihan MM, et al: The impact of chelation
337(26):1870–1875, 1997. therapy on survival in transfusional iron overload: a meta-analysis of
417. Wandt H, Schaefer-Eckart K, Wendelin K, et al: Therapeutic platelet myelodysplastic syndrome. Br J Haematol 167(5):720–723, 2014.
transfusion versus routine prophylactic transfusion in patients with 438. Bennett JM, MDS Foundation’s Working Group on Transfusional Iron
haematological malignancies: an open-label, multicentre, randomised Overload: Consensus statement on iron overload in myelodysplastic
study. Lancet 380(9850):1309–1316, 2012. syndromes. Am J Hematol 83(11):858–861, 2008.
418. Bussel JB, Cheng G, Saleh MN, et al: Eltrombopag for the treat- 439. Armand P, Kim HT, Cutler CS, et al: Prognostic impact of elevated
ment of chronic idiopathic thrombocytopenic purpura. N Engl J Med pretransplantation serum ferritin in patients undergoing myeloablative
357(22):2237–2247, 2007. stem cell transplantation. Blood 109(10):4586–4588, 2007.
419. Kuter DJ, Begley CG: Recombinant human thrombopoietin: basic 440. Di Tucci AA, Matta G, Deplano S, et al: Myocardial iron overload
biology and evaluation of clinical studies. Blood 100(10):3457–3469, assessment by T2* magnetic resonance imaging in adult transfusion
2002. dependent patients with acquired anemias. Haematologica 93(9):1385–
420. Kantarjian H, Fenaux P, Sekeres MA, et al: Safety and efficacy of 1388, 2008.
romiplostim in patients with lower-risk myelodysplastic syndrome and 441. List AF: New approaches to the treatment of myelodysplasia. Oncologist
thrombocytopenia. J Clin Oncol 28(3):437–444, 2010. 7(Suppl 1):39–49, 2002.
421. Kantarjian HM, Giles FJ, Greenberg PL, et al: Phase 2 study of romiplos- 442. Krönke J, Fink EC, Hollenbach PW, et al: Lenalidomide induces
tim in patients with low- or intermediate-risk myelodysplastic syndrome ubiquitination and degradation of CK1α in del(5q) MDS. Nature
receiving azacitidine therapy. Blood 116(17):3163–3170, 2010. 523(7559):183–188, 2015.
422. Sekeres MA, Kantarjian H, Fenaux P, et al: Subcutaneous or intrave- 443. Fink EC, Krönke J, Hurst SN, et al: Lenalidomide Induces Ubiquitina-
nous administration of romiplostim in thrombocytopenic patients with tion and Degradation of CSNK1A1 in MDS with Del(5q). Blood
lower risk myelodysplastic syndromes. Cancer 117(5):992–1000, 2011. 124:4, 2014.
423. Greenberg PL, Garcia-Manero G, Moore M, et al: A randomized 444. List A, Kurtin S, Roe DJ, et al: Efficacy of lenalidomide in myelodys-
controlled trial of romiplostim in patients with low- or intermediate- plastic syndromes. N Engl J Med 352(6):549–557, 2005.
risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma 445. Raza A, Reeves JA, Feldman EJ, et al: Phase 2 study of lenalidomide
54(2):321–328, 2013. in transfusion-dependent, low-risk, and intermediate-1 risk myelo-
424. Svensson T, Chowdhury O, Garelius H, et al: A pilot phase I dose finding dysplastic syndromes with karyotypes other than deletion 5q. Blood
safety study of the thrombopoietin-receptor agonist, eltrombopag, in 111(1):86–93, 2008.
patients with myelodysplastic syndrome treated with azacitidine. Eur J 446. Santini V, Prebet T, Fenaux P, et al: Minimizing risk of hypomethylating
Haematol 93(5):439–445, 2014. agent failure in patients with higher-risk MDS and practical manage-
425. Kuter DJ, Mufti GJ, Bain BJ, et al: Evaluation of bone marrow reticulin ment recommendations. Leuk Res 38(12):1381–1391, 2014.
formation in chronic immune thrombocytopenia patients treated with 447. Sekeres MA, Maciejewski JP, Giagounidis AAN, et al: Relationship
romiplostim. Blood 114(18):3748–3756, 2009. of treatment-related cytopenias and response to lenalidomide in
426. Brierley CK, Steensma DP: Thrombopoiesis-stimulating agents and patients with lower-risk myelodysplastic syndromes. J Clin Oncol
myelodysplastic syndromes. Br J Haematol 2015. 26(36):5943–5949, 2008.
427. Giagounidis A, Mufti GJ, Fenaux P, et al: Results of a randomized, 448. Richardson P, Jagannath S, Hussein M, et al: Safety and efficacy of
double-blind study of romiplostim versus placebo in patients with low/ single-agent lenalidomide in patients with relapsed and refractory
intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. multiple myeloma. Blood 114(4):772–778, 2009.
Cancer 120(12):1838–1846, 2014. 449. Wisch JS, Griffin JD, Kufe DW: Response of preleukemic syndromes
428. Giardina PJ, Grady RW: Chelation therapy in beta-thalassemia: an to continuous infusion of low-dose cytarabine. N Engl J Med
optimistic update. Semin Hematol 38(4):360–366, 2001. 309(26):1599–1602, 1983.
429. Lyons RM, Marek BJ, Paley C, et al: Comparison of 24-month outcomes 450. Mufti GJ, Oscier DG, Hamblin TJ, et al: Low doses of cytarabine in the
in chelated and non-chelated lower-risk patients with myelodysplastic treatment of myelodysplastic syndrome and acute myeloid leukemia. N
syndromes in a prospective registry. Leuk Res 38(2):149–154, 2014. Engl J Med 309(26):1653–1654, 1983.